1-Isopropoxynonane | 138905-27-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-Isopropoxynonane
• 英文别名: isopropyl nonyl ether；1-(1-methylethoxy)-nonane；1-Propan-2-yloxynonane
• CAS: 138905-27-8
• 化学式: C₁₂H₂₆O
• 分子量: 186.338
• InChiKey: UVMFRDDJIGOZSX-UHFFFAOYSA-N

物化性质

• 沸点：
  211.6±3.0 °C(Predicted)
• 密度：
  0.798±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  13
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-壬醇 在 对甲苯磺酸 作用下， 以 乙醚 、 甲苯 为溶剂， 反应 0.25h， 生成 1-Isopropoxynonane
  参考文献：
  名称：

  Willson, Timothy M.; Amburgey, Jack; Denmark, Scott E., Journal of the Chemical Society. Perkin transactions I, 1991, # 12, p. 2899 - 2906

  摘要：

  DOI：

文献信息

• [EN] SMARCA DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION DE SMARCA ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2020251971A1

  公开（公告）日：2020-12-17

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same for the modulation of one or more SWI/SNF-related matrix associated actin dependent regulator of chromatin subfamily A (SMARCA) and/or polybromo-1 (PB-1) protein via ubiqitination and/or degradation by compounds. The compounds are bifunctional molecules that link a cereblon-binding moiety to a ligand that binds SMARCA and/or PB1 proteins.

  本发明提供化合物、其药学上可接受的组合物，以及利用这些化合物调控一个或多个SWI/SNF相关基质相关肌动蛋白依赖的染色质亚家族A（SMARCA）和/或聚溴-1（PB-1）蛋白通过化合物的泛素化和/或降解的方法。这些化合物是双功能分子，将结合到cereblon的部分与结合到SMARCA和/或PB1蛋白的配体连接在一起。
• Process for producing alpha-olefin
  申请人：KURARAY CO., LTD

  公开号：US20030065233A1

  公开（公告）日：2003-04-03

  A production process for &agr;-olefins making use of elimination reaction of a primary alcohol or an ether is characterized by use of an alumina catalyst in the presence of an amine. The production process for &agr;-olefins according to the present invention can yield an &agr;-olefin at a high proportion with respect to the entire olefin products and can maintain the reactivity of the catalyst and selectivity of the products for a prolonged time. In the process, unreacted material and ether intermediate byproduct produced in the process can be used in the reaction with the same catalyst. This allows industrially and environmentally favorable production process of &agr;-olefins.

  一种生产α-烯烃的生产工艺，利用一次醇或醚的消除反应，其特征在于在胺的存在下使用氧化铝催化剂。根据本发明的α-烯烃生产工艺可以高比例地产生α-烯烃，同时可以长时间保持催化剂的反应性和产品的选择性。在该过程中，未反应的物料和过程中产生的醚中间体副产物可以与相同的催化剂一起用于反应。这使得α-烯烃的工业和环境友好的生产工艺成为可能。
• COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM
  申请人：Takayama Masami

  公开号：US20090318513A1

  公开（公告）日：2009-12-24

  A compound represented by the general formula (I): wherein R 1 is a hydrogen atom, a halogen atom, or the like; R 2 , R 3 , and R 4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 are a hydrogen atom or the like; R 8 is C1-C3 alkyl or the like; R 9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.

  一种由通式（I）表示的化合物：其中R1是氢原子、卤素原子或类似物；R2、R3和R4各自独立地是氢原子、卤素原子、C1-C15烷基（可选地用一个或多个C1-C12烷氧基或类似物取代）或类似物；R5是氢原子或类似物；R6和R7是氢原子或类似物；R8是C1-C3烷基或类似物；R9是氢原子或类似物。该化合物为一种前药、药物可接受的盐或其溶剂。
• Compounds exhibiting thrombopoietin receptor agonism
  申请人：Takayama Masami

  公开号：US20070043087A1

  公开（公告）日：2007-02-22

  A compound represented by the general formula (I): wherein R 1 is a hydrogen atom, a halogen atom, or the like; R 2 , R 3 , and R 4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 are a hydrogen atom or the like; R 8 is C1-C3 alkyl or the like; R 9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.

  化合物的一般式(I)表示的复合物，其中R1是氢原子、卤素原子或类似物；R2、R3和R4各自独立地是氢原子、卤素原子、C1-C15烷基（可选地用一个或多个C1-C12烷氧基或类似物取代）或类似物；R5是氢原子或类似物；R6和R7是氢原子或类似物；R8是C1-C3烷基或类似物；R9是氢原子或类似物。这是一个前药、药物可接受的盐或其溶剂。
• PSEUDONUCLEOTIDE COMPRISING AN INTERCALATOR
  申请人：Christensen Ulf Bech

  公开号：US20100121056A1

  公开（公告）日：2010-05-13

  The present invention relates to intercalator pseudonucleotides. Intercalator pseudonucleotides according to the invention are capable of being incorporated into the backbone of a nucleic acid or nucleic acid analogue and they comprise an intercalator comprising a flat conjugated system capable of co-stacking with nucleobases of DNA. The invention also relates to oligonucleotides or oligonucleotide analogues comprising at least one intercalator pseudo nucleotide. The invention furthermore relates to methods of synthesising intercalator pseudo nucleotides and methods of synthesising oligonucleotides or oligonucleotide analogues comprising at least one intercalator pseudonucleotide. In addition, the invention describes methods of separating sequence specific DNA(s) from a mixture comprising nucleic acids, methods of detecting a sequence specific DNA (target DNA) in a mixture comprising nucleic acids and/or nucleic acid analogues and methods of detecting a sequence specific RNA in a mixture comprising nucleic acids and/or nucleic acid analogues. In particular said methods may involve the use of oligonucleotides comprising intercalator pseudo nucleotides. The invention furthermore relates to pairs of oligonucleotides or oligonucleotide analogues capable of hybridising to one another, wherein said pairs comprise at least one intercalator pseudonucleotide. Methods for inhibiting a DNAse and/or a RNAse and methods of modulating transcription of one or more specific genes are also described.

  本发明涉及插入剂伪核苷酸。本发明的插入剂伪核苷酸能够被合并到核酸或核酸类似物的骨架中，并且它们包括一个插入剂，该插入剂包含一个平面共轭系统，能够与DNA的碱基共堆叠。本发明还涉及至少包括一个插入剂伪核苷酸的寡核苷酸或寡核苷酸类似物。此外，本发明还涉及合成插入剂伪核苷酸的方法以及合成至少包括一个插入剂伪核苷酸的寡核苷酸或寡核苷酸类似物的方法。此外，本发明还描述了从包括核酸的混合物中分离序列特异性DNA的方法，检测包括核酸和/或核酸类似物的混合物中的序列特异性DNA（目标DNA）的方法，以及检测包括核酸和/或核酸类似物的混合物中的序列特异性RNA的方法。特别是所述方法可能涉及使用包括插入剂伪核苷酸的寡核苷酸。本发明还涉及能够杂交到一起的寡核苷酸或寡核苷酸类似物的配对，其中所述配对包括至少一个插入剂伪核苷酸。还描述了抑制DNA酶和/或RNA酶的方法以及调节一个或多个特定基因的转录的方法。